Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Dendreon’s Los Angeles Cancer Immunotherapy Manufacturing Facility

By Pharmaceutical Processing | June 30, 2011

Dendreon Corporation has announced that the FDA approved its
Los Angeles cancer immunotherapy manufacturing facility, allowing the company
to continue to increase the availability of PROVENGE® (sipuleucel-T) across the
U.S. to help meet the needs of patients with asymptomatic or minimally
symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
 

 

The Los Angeles
facility includes 36 workstations, and Dendreon will bring these new workstations
online in a staged approach. With this FDA approval and the fully approved New Jersey facility,
Dendreon now has total of 84 workstations available to manufacture PROVENGE.
Dendreon expects to continue to provide additional capacity through the anticipated
licensure mid-year of one other manufacturing facility in the United States.
 In April, Dendreon filed a post-approval supplement for its third
facility in Atlanta,
for which there is an FDA action date of August 28, 2011.

 

PROVENGE is designed to induce an immune response against
prostatic acid phosphatase (PAP), an antigen expressed in most prostate
cancers, and is the first in a new therapeutic class of drugs known as
autologous cellular immunotherapies.

 

“As the foundation of care, PROVENGE is an important
treatment option for men with metastatic castrate resistant prostate
cancer,” said Mitchell H. Gold, M.D., president and chief executive
officer of Dendreon. “The FDA approval of the Los Angeles facility will enhance our ability
to provide PROVENGE to the many patients across the country who may benefit
from it.”  

 

In anticipation of the availability of the additional
workstations, Dendreon expects to have approximately 225 active infusing sites
by the end of the second quarter and approximately 500 by the end of 2011.

 

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE